High-dose ubiquinol supplementation in multiple-system atrophy: a multicentre, randomised, double-blinded, placebo-controlled phase 2 trial
Jun Mitsui,Takashi Matsukawa,Yukari Uemura,Takuya Kawahara,Ayaka Chikada,Kristine Joyce L Porto,Hiroya Naruse,Masaki Tanaka,Hiroyuki Ishiura,Tatsushi Toda,Haruko Kuzuyama,Mari Hirano,Ikue Wada,Toshio Ga,Takashi Moritoyo,Yuji Takahashi,Hidehiro Mizusawa,Kinya Ishikawa,Takanori Yokota,Satoshi Kuwabara,Nobukatsu Sawamoto,Ryosuke Takahashi,Koji Abe,Tomohiko Ishihara,Osamu Onodera,Dai Matsuse,Ryo Yamasaki,Jun-Ichi Kira,Masahisa Katsuno,Ritsuko Hanajima,Katsuhisa Ogata,Hiroshi Takashima,Masaaki Matsushima,Ichiro Yabe,Hidenao Sasaki,Shoji Tsuji
DOI: https://doi.org/10.1016/j.eclinm.2023.101920
IF: 15.1
2023-04-14
EClinicalMedicine
Abstract:Background: Functionally impaired variants of COQ2, encoding an enzyme in biosynthesis of coenzyme Q10 (CoQ10), were found in familial multiple system atrophy (MSA) and V393A in COQ2 is associated with sporadic MSA. Furthermore, reduced levels of CoQ10 have been demonstrated in MSA patients. Methods: This study was a multicentre, randomised, double-blinded, placebo-controlled phase 2 trial. Patients with MSA were randomly assigned (1:1) to either ubiquinol (1500 mg/day) or placebo. The primary efficacy outcome was the change in the unified multiple system atrophy rating scale (UMSARS) part 2 at 48 weeks. Efficacy was assessed in all patients who completed at least one efficacy assessment (full analysis set). Safety analyses included patients who completed at least one dose of investigational drug. This trial is registered with UMIN-CTR (UMIN000031771), where the drug name of MSA-01 was used to designate ubiquinol. Findings: Between June 26, 2018, and May 27, 2019, 139 patients were enrolled and randomly assigned to the ubiquinol group (n = 69) or the placebo group (n = 70). A total of 131 patients were included in the full analysis set (63 in the ubiquinol group; 68 in the placebo group). This study met the primary efficacy outcome (least square mean difference in UMSARS part 2 score (-1.7 [95% CI, -3.2 to -0.2]; P = 0.023)). The ubiquinol group also showed better secondary efficacy outcomes (Barthel index, Scale for the Assessment and Rating of Ataxia, and time required to walk 10 m). Rates of adverse events potentially related to the investigational drug were comparable between ubiquinol (n = 15 [23.8%]) and placebo (n = 21 [30.9%]). Interpretation: High-dose ubiquinol was well-tolerated and led to a significantly smaller decline of UMSARS part 2 score compared with placebo. Funding: Japan Agency for Medical Research and Development.